Drug Discovery

InveniAI Collaborates with Shionogi on AI-Based Drug Discovery

  • by

Shots: InveniAI is eligible to receive up to $200M/ program as up front, development, and commercial milestones along with royalties The collaboration integrates InveniAI’s AI platform AlphaMeld to identify, evaluate, optimize novel targets with Shionogi’s expertise in developing and commercializing therapeutic modalities Shionogi will synthesize… Read More »InveniAI Collaborates with Shionogi on AI-Based Drug Discovery

Here’s a look at natural product drug discovery 2.0

  • by

Plant-based drug discovery may be tens of thousands of years old, but in 2021, it feels exciting, rich, and full of potential. Companies are rapidly building scalable databases with hundreds of thousands of unique chemicals and their links to biological signatures.

UCB Collaborates with Microsoft to Accelerate Drug Discovery and Development

  • by

Shots: The collaboration will merge Microsoft’s computational services, cloud and AI with UCB’s drug discovery and development capabilities The companies intend to discover and develop medicines for people living with severe diseases in immunology and neurology. The collaboration follows UCB and Microsoft’s collaboration around COVID-19… Read More »UCB Collaborates with Microsoft to Accelerate Drug Discovery and Development

Microsoft, UCB Launch Collaboration to Accelerate Drug Discovery and Development

  • by

What You Should Know: – Global biopharma company UCB and Microsoft announced today a new, multi-year strategic collaboration to advance UCB’s digital transformation, change the way care is delivered, and accelerate better outcomes for people living with severe diseases. – The partnership builds on the companies’ joint… Read More »Microsoft, UCB Launch Collaboration to Accelerate Drug Discovery and Development

Alzheimer’s Research UK starts AI-based drug hunt with Exscientia

  • by

Medical charity Alzheimer’s Research UK has teamed up with artificial intelligence specialist Exscientia to find new drug treatments for the devastating neurodegenerative disease.  The alliance will see Exscientia work with the charity’s Oxford Drug Discovery Institute (ODDI) to find therapeutics that target the neuroinflammation associated… Read More »Alzheimer’s Research UK starts AI-based drug hunt with Exscientia

Evotec Collaborates with Related Sciences for Drug Discovery and Development

  • by

Shots: Evotec to receive milestones, royalties, and a founding equity stake in all Related Sciences assets developed under the collaboration Evotec and Related Sciences will jointly discover & develop a multitude of therapeutic approaches with IND filings over a multi-year period. The partnership will combine… Read More »Evotec Collaborates with Related Sciences for Drug Discovery and Development

Artificial Intelligence in Drug Discovery – Could help Reduce Significant Capital and Time Required

  • by

Drug discovery is a complex process which involves significant utilization of time and resources. As per several sources, on an average, the entire drug development process (from initial proof-of-concept to commercial launch) takes around 10-15 years and capital investments worth USD 4-10 billion to develop… Read More »Artificial Intelligence in Drug Discovery – Could help Reduce Significant Capital and Time Required

Advancing Healthcare Delivery via Artificial Intelligence

  • by

Artificial Intelligence have demonstrated intelligent behavior through their ability to learn, communicate with its users and solve complex problems using highly sophisticated algorithms. AI-driven technologies have continued to evolve rapidly, with several industries increasingly deploying such solutions across key aspects of value chain. Furthermore, AI… Read More »Advancing Healthcare Delivery via Artificial Intelligence

Roche Collaborate with Cambridge Quantum Computing to Develop Quantum Algorithm for Drug Discovery and Development

  • by

Shots: CQC collaborates with Roche to design and implement noisy-intermediate-scale-quantum (NISQ) algorithms for early-stage drug discovery and development The collaboration will employ CQC’s quantum chemistry platform ‘EUMEN’, to augment the Roche’s AD research efforts The multi-year collaboration will combine the expertise of both CQC and… Read More »Roche Collaborate with Cambridge Quantum Computing to Develop Quantum Algorithm for Drug Discovery and Development

30 Executives Share Top Healthcare Predictions & Trends to Watch in 2021

  • by

As we close out the year, we asked several healthcare executives to share their predictions and trends for 2021. Kimberly Powell, Vice President & General Manager, NVIDIA Healthcare Federated Learning: The clinical community will increase their use of federated learning approaches to build robust AI models across various… Read More »30 Executives Share Top Healthcare Predictions & Trends to Watch in 2021

Johnson & Johnson Innovation Launches 3 Collaborations to Advance Healthcare in China

  • by

Front row (left to right): Jian Chen, Vice President, Xian Janssen Pharmaceuticals; Dan Wang, Head, Johnson & Johnson Innovation, Asia Pacific; Sharona Tao, Leader, Communications & Public Affairs, Johnson & Johnson China; Jennifer Yang, Head, Lung Cancer Initiative China, Johnson & Johnson Back row (left… Read More »Johnson & Johnson Innovation Launches 3 Collaborations to Advance Healthcare in China

Mission Bio Launches Single-Cell Multi-Omics System for Precision Cancer Therapies

  • by

What You Should Know: – Mission Bio launches industry’s first and only single-cell multi-omics platform, is announcing the launch of its most comprehensive instrument to-date, to save the industry billions of dollars in drug development costs and bring life-saving treatments to market at least six… Read More »Mission Bio Launches Single-Cell Multi-Omics System for Precision Cancer Therapies

BMS joins forces with insitro to develop neurodegenerative treatments

  • by

insitro has landed another big biopharma partnership, signing a five-year collaboration with Bristol Myers Sqibb to develop therapies for amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD).  Neurodegenerative disorders such as ALS and FTD are considered a challenging therapeutic area, with no disease modifying treatments… Read More »BMS joins forces with insitro to develop neurodegenerative treatments

JPC Taps Proscia to Modernize World’s Largest Human Tissue Repository

  • by

What You Should Know: – The U.S. government’s Joint Pathology Center, which houses the world’s largest human tissue repository, today announced that Proscia, a leading digital and AI pathology company, will provide end-to-end modernization of JPC’s pathology operations. – The multi-phase project will digitize the… Read More »JPC Taps Proscia to Modernize World’s Largest Human Tissue Repository

AI drug-discovery firm lands first partnership

  • by

The deal with Roche subsidiary Genentech is likely not the last for Genesis Therapeutics, which is based on AI research undertaken at Stanford. Such partnerships are potentially lucrative for drug-discovery startups.

Scripps Research, Repurpose.AI Partner to Develop COVID-19 Therapeutics

  • by

What You Should Know: – Repurpose.AI, has partnered with Scripps Research to discover drug candidates that may be repurposed to treat COVID-19.  – The partnership will leverage Repurpose.AI’s ActivPred AI Drug Discovery Platform, an unbiased drug, target, and disease agnostic digital chemistry engine, to discover… Read More »Scripps Research, Repurpose.AI Partner to Develop COVID-19 Therapeutics

Increasing Rate of Drug Failure has Prompted the Drug Developers to Rely on CROs offering In Vitro ADME Testing Services for their Outsourcing Requirements

It is important to note that the process of drug discovery is extremely demanding, both in terms of capital and time. In fact, the overall amount spent on R&D initiatives in the pharmaceutical / biotechnology sector has increased from around USD 128 billion in 2008… Read More »Increasing Rate of Drug Failure has Prompted the Drug Developers to Rely on CROs offering In Vitro ADME Testing Services for their Outsourcing Requirements

Rising Popularity of Drug Targeting Synthetically Lethal Targets Fuels the Battle of PARP Inhibitors for Treatment of Advanced Cancer Indications

  • by

Cancer is considered to be the second leading cause of mortality, after cardiovascular diseases, accounting for every sixth reported death in the world. The International Agency for Research on Cancer (IARC) states that the number of new cancer cases is expected to grow to 27.5… Read More »Rising Popularity of Drug Targeting Synthetically Lethal Targets Fuels the Battle of PARP Inhibitors for Treatment of Advanced Cancer Indications

Targeted Protein Degradation – Defining a New Frontier in the Field of Medicine

  • by

The concept of targeted protein degradation presents revolutionary drug development opportunities and is anticipated to bring about a paradigm shift in modern healthcare. While conventional medicines, such as small molecule inhibitors and monoclonal antibodies, address fewer than 20% of the proteome, targeted protein degradation offers… Read More »Targeted Protein Degradation – Defining a New Frontier in the Field of Medicine

In Silico / Computer-Aided Drug Discovery Service Providers for Large Molecules

  • by

Over time, the complexities associated with drug discovery have increased, especially in case of large molecule drugs, which are inherently more complex than conventional small molecules. As a result, an increase in the overall research and development (R&D) expenditure in the pharmaceutical / biotechnology sector… Read More »In Silico / Computer-Aided Drug Discovery Service Providers for Large Molecules